CMS Sets Reimbursement Rate for Eko Health’s AI Cardiac Analysis Tool

Eko Health has been awarded a Centers for Medicare & Medicaid Services (CMS) reimbursement rate for the SENSORA platform, helping foster the broader adoption of the artificial intelligence-powered cardiac analysis solution.

In its July 2025 provisional update to the Hospital Outpatient Prospective Payment System (OPPS), CMS assigns SENSORA’s Category III CPT code to APC 5734, with a $128.90 reimbursement rate per use. The

The ruling represents a pivotal reimbursement milestone for deploying SENSORA as part of routine hospital outpatient cardiac evaluations, according to Eko Health. Hospitals and health systems now have a clear financial pathway to implement AI-enabled auscultation and ECG analysis for identifying serious cardiovascular conditions at the point of care.

Additionally, the Category III CPT code issued by the American Medical Association (AMA) for SENSORA officially took effect on July 1, marking the growing institutional recognition of algorithmic cardiac support tools’ clinical utility.

“This CPT code signals the growing importance of AI in point-of-care detection,” Eko Health Co-Founder/CEO Connor Landgraf said. “It’s crucial to create payment models that compensate front-line providers for the additional time they spend caring for complex cardiac patients. To beat our heart disease epidemic, it’s absolutely essential for front-line providers to be empowered with advanced tools like SENSORA to identify cardiovascular disease earlier and more accurately.”

Heart disease remains the leading cause of death in the United States, responsible for nearly one in five deaths according to the CDC. Yet heart conditions such as low ejection fraction, valvular heart disease, and atrial fibrillation are frequently missed in routine exams—especially in time-limited care settings. SENSORA addresses these diagnostic gaps by delivering real-time AI analysis in under a minute, enabling earlier detection of structural murmurs, low ejection fraction (Low EF), and atrial fibrillation (AFib) using Eko’s ECG-enabled digital stethoscopes.

“We’ve reached a pivotal moment in the application of AI in medicine, not as a future promise, but as a present tool for improving access and accuracy,” said Dr. Steven Steinhubl, cardiologist and chair of Eko’s Clinical Advisory Board. “SENSORA’s ability to empower clinicians with real-time insights is a breakthrough in the fight against undertreated heart disease.”

SENSORA’s algorithms have been clinically validated and published in high-impact journals including the Journal of American Heart Association and JACC Advances, establishing a strong foundation of peer-reviewed evidence.

A prospective multicenter study published in The Lancet Digital Health validated SENSORA’s Low Ejection Fraction algorithm, demonstrating 85% sensitivity and 70% specificity from a single auscultation point, enabling earlier identification of certain forms of heart failure.

A separate study published in Circulation showed that SENSORA more than doubled the sensitivity of structural murmur detection compared to standard auscultation (90% vs. 43%), improving the identification of valvular heart disease in time-limited clinical settings.

These findings reinforce the urgency and impact of deploying U.S. Food and Drug Administration (FDA)-cleared, AI-powered detection tools like SENSORA in everyday practice—especially where early intervention can improve outcomes, the company claims.

SENSORA is Eko Health’s FDA-cleared and clinically validated AI platform that brings advanced cardiac analysis to the front lines of care. Integrated with Eko’s digital stethoscopes, SENSORA delivers real-time, assistive insights during routine exams—helping clinicians identify structural murmurs, low ejection fraction (Low EF), and atrial fibrillation (AFib) with greater confidence. Designed for seamless implementation in clinical workflows, SENSORA offers a scalable, point-of-care solution to improve early detection and bridge gaps in access to specialty-level cardiac evaluation.

Eko Health is an AI early disease detection company advancing the way healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes and ECG devices, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, with more than 650,000 devices sold to providers globally, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, Calif.

To support adoption and reimbursement readiness, Eko has launched a new resource center where providers and health systems can learn more and access a Coding Guide.